Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IgPro10 (Privigen) for diffuse systemic sclerosis
2019-000906-31Phase 2Terminated
- Sponsor
- CSL Limited
- Start
- Oct 2019
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in systemic sclerosis (SSc) comparing Privigen with Placebo (2 arms). Primary endpoint: Response on American College of Rheumatology Combined Response Index in Diffuse Systemic Sclerosis (ACR CRISS) score in IgPro10 vs Placebo. Started Oct 2019; status: terminated.
02
Drugs
polyvalent human immunoglobulin
03
Conditions
systemic sclerosis (SSc)
Beyond the preview
Go deeper on 2019-000906-31.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2019-000906-31.